Abstract:Cancer is a disease caused by the uncontrolled, abnormal growth of cells in different anatomic sites. In 2018, it was predicted that the worldwide cancer burden would rise to 18.1 million new cases and 9.6 million deaths. Anticancer compounds, often known as chemotherapeutic medicines, have gained much interest in recent cancer research. These medicines work through various biological processes in targeting cells at various stages of the cell's life cycle. One of the most significant roadblocks to developing anticancer drugs is that traditional chemotherapy affects normal cells and cancer cells, resulting in substantial side effects. Recently, advancements in new drug development methodologies and the prediction of the targeted interatomic and intermolecular ligand interaction sites have been beneficial. This has prompted further research into developing and discovering novel chemical species as preferred therapeutic compounds against specific cancer types. Identifying new drug molecules with high selectivity and specificity for cancer is a prerequisite in the treatment and management of the disease. The overexpression of HSP90 occurs in patients with cancer, and the HSP90 triggers unstable harmful kinase functions, which enhance carcinogenesis. Therefore, the development of potent HSP90 inhibitors with high selectivity and specificity becomes very imperative. The activities of HSP90 as chaperones and cochaperones are complex due to the conformational dynamism, and this could be one of the reasons why no HSP90 drugs have made it beyond the clinical trials. Nevertheless, HSP90 modulations appear to be preferred due to the competitive inhibition of the targeted N-terminal adenosine triphosphate pocket. This study, therefore, presents an overview of the various computational models implored in the development of HSP90 inhibitors as anticancer medicines. We hereby suggest an extensive investigation of advanced computational modelling of the three different domains of HSP90 for potent, effective inhibitor design with minimal off-target effects.

The Investigation of Hsp90 C‐terminal inhibitors containing Amide bioisosteres

Inhibitors of the HSP90 Molecular Chaperone: Current Status

Insight into the structural and dynamic properties of novel HSP90 inhibitors through DFT calculations and molecular dynamics simulations

Discovery of Potent N-(isoxazol-5-yl)amides As HSP90 Inhibitors.

Assay design and development strategies for finding Hsp90 inhibitors and their role in human diseases

Probing some recent natural compounds from Phellinus baumii, Colletotrichum sp. and Ligustrum lucidum as heat shock protein 90 inhibitors

HSP90 as a new therapeutic target for cancer therapy: the story unfolds

Natural compounds as potential Hsp90 inhibitors for breast cancer-Pharmacophore guided molecular modelling studies

Alternate Strategies of Hsp90 Modulation for the Treatment of Cancer and Other Diseases

Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

Small-molecule dual inhibitors targeting heat shock protein 90 for cancer targeted therapy

Discovery of new Hsp90-Cdc37 protein-protein interaction inhibitors: in silico screening and optimization of anticancer activity

Design, synthesis and biological evaluation of a new class of Hsp90 inhibitors vibsanin C derivatives

Hsp90 Inhibitors as Anti-Cancer Agents, from Basic Discoveries to Clinical Development

Discovery and development of heat shock protein 90 inhibitors.

Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer

Design, synthesis and biological studies of new isoxazole compounds as potent Hsp90 inhibitors

Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance

Heat Shock Protein 90 (HSP90) Inhibitors as Anticancer Medicines: A Review on the Computer-Aided Drug Discovery Approaches over the Past Five Years

Targeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects